HUTCHMED China Ltd (HCM) - Cash Flow Conversion Efficiency

Latest as of June 2025: -0.029x

Based on the latest financial reports, HUTCHMED China Ltd (HCM) has a cash flow conversion efficiency ratio of -0.029x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (GBX-36.45 Million ≈ $-4.43K USD) by net assets (GBX1.24 Billion ≈ $151.11K USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See HCM net asset quality index to measure how much of total assets are equity-financed.

HUTCHMED China Ltd - Cash Flow Conversion Efficiency Trend (2005–2025)

This chart illustrates how HUTCHMED China Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check HCM cash flow quality index to evaluate the quality of earnings relative to operating cash generation.

HUTCHMED China Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of HUTCHMED China Ltd ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
Greenwing Resources Ltd
AU:GW1
0.008x
Job Solution Sweden Holding AB
ST:JOBS
-0.019x
New Zealand Energy Corp
V:NZ
-0.372x
Astral Asia Bhd
KLSE:7054
0.003x
Trilogiq
PA:ALTRI
0.004x
Pungkang Co. Ltd
KQ:093380
0.048x
Keyware Technologies NV
BR:KEYW
0.016x
Polylite Taiwan Co Ltd
TWO:1813
0.109x

Annual Cash Flow Conversion Efficiency for HUTCHMED China Ltd (2005–2025)

The table below shows the annual cash flow conversion efficiency of HUTCHMED China Ltd from 2005 to 2025. For the full company profile with market capitalisation and key ratios, see HCM market cap overview.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2025-12-31 GBX1.25 Billion
≈ $152.03K
GBX-64.67 Million
≈ $-7.87K
-0.052x -8137.94%
2024-12-31 GBX771.85 Million
≈ $93.91K
GBX497.00K
≈ $60.47
0.001x -99.78%
2023-12-31 GBX743.39 Million
≈ $90.45K
GBX219.26 Million
≈ $26.68K
0.295x +169.93%
2022-12-31 GBX636.87 Million
≈ $77.49K
GBX-268.60 Million
≈ $-32.68K
-0.422x -114.67%
2021-12-31 GBX1.04 Billion
≈ $126.48K
GBX-204.22 Million
≈ $-24.85K
-0.196x -64.27%
2020-12-31 GBX518.95 Million
≈ $63.14K
GBX-62.07 Million
≈ $-7.55K
-0.120x +53.75%
2019-12-31 GBX312.90 Million
≈ $38.07K
GBX-80.91 Million
≈ $-9.84K
-0.259x -224.54%
2018-12-31 GBX412.25 Million
≈ $50.16K
GBX-32.85 Million
≈ $-4.00K
-0.080x -332.07%
2017-12-31 GBX484.97 Million
≈ $59.01K
GBX-8.94 Million
≈ $-1.09K
-0.018x +60.68%
2016-12-31 GBX204.06 Million
≈ $24.83K
GBX-9.57 Million
≈ $-1.16K
-0.047x +48.90%
2015-12-31 GBX102.28 Million
≈ $12.44K
GBX-9.38 Million
≈ $-1.14K
-0.092x -182.34%
2014-12-31 GBX119.88 Million
≈ $14.59K
GBX13.36 Million
≈ $1.63K
0.111x +132.36%
2013-12-31 GBX104.84 Million
≈ $12.76K
GBX5.03 Million
≈ $611.76
0.048x -74.38%
2012-12-31 GBX83.65 Million
≈ $10.18K
GBX15.66 Million
≈ $1.91K
0.187x +178.34%
2011-12-31 GBX77.33 Million
≈ $9.41K
GBX5.20 Million
≈ $632.88
0.067x +123.36%
2010-12-31 GBX68.81 Million
≈ $8.37K
GBX-19.82 Million
≈ $-2.41K
-0.288x -286.53%
2009-12-31 GBX75.30 Million
≈ $9.16K
GBX11.63 Million
≈ $1.41K
0.154x +191.37%
2008-12-31 GBX84.43 Million
≈ $10.27K
GBX-14.27 Million
≈ $-1.74K
-0.169x -91.86%
2007-12-31 GBX97.61 Million
≈ $11.88K
GBX-8.60 Million
≈ $-1.05K
-0.088x -166.27%
2006-12-31 GBX109.98 Million
≈ $13.38K
GBX-3.64 Million
≈ $-442.64
-0.033x -106.81%
2005-12-31 GBX-28.01 Million
≈ $-3.41K
GBX-13.60 Million
≈ $-1.65K
0.485x --

About HUTCHMED China Ltd

LSE:HCM UK Drug Manufacturers - Specialty & Generic
Market Cap
$17.36 Million
GBX142.72 Billion GBX
Market Cap Rank
#25533 Global
#274 in UK
Share Price
GBX166.00
Change (1 day)
-3.63%
52-Week Range
GBX156.00 - GBX286.00
All Time High
GBX624.00
About

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong Kong, the United States, and internationally. It provides Fruquintinib, a selective and potent oral inhibitor of vascular endothelial growth factor receptors for treatment of colorectal cancer (CRC), breast c… Read more